CNS Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M |
| Operating expenses | $16.0M | $14.9M | $18.9M | $15.3M | $14.5M |
| Operating income | -$16.0M | -$14.9M | -$18.9M | -$15.3M | -$14.5M |
| Interest expense | $15,230 | $16,120 | $13,805 | $7,027 | $9,285 |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.9M | -$14.9M | -$18.9M | -$15.3M | -$14.5M |
| Balance Sheet | |||||
| Cash and equivalents | $7.2M | $6.5M | $548,721 | $10.1M | $5.0M |
| Current assets | $8.1M | $8.7M | $1.6M | $12.6M | $7.5M |
| Total assets | $8.6M | $8.7M | $1.7M | $13.1M | $8.8M |
| Current liabilities | $4.1M | $2.5M | $6.1M | $4.9M | $2.6M |
| Total liabilities | $4.1M | $2.5M | $6.1M | $4.9M | $2.6M |
| Stockholders' equity | $4.5M | $6.2M | -$4.4M | $8.1M | $6.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M |
| Depreciation and amortization | $3,918 | $3,306 | $4,134 | $11,756 | $13,070 |
| Stock-based compensation | $187,728 | $838,957 | $1.0M | $1.2M | $1.7M |
| Capital expenditure | $18,175 | $4,188 | $3,901 | $4,422 | $5,748 |
| Free cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M |
Shares outstanding 1.5M · Free float 49.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.